SCHEMBL24155474

SCHEMBL24155474

O=C1CCN(c2ccc(Oc3ccccc3)cc2)C(=O)N1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 10/20 0.73
DDB1 Q16531 9/20 0.73
PLCG1 P19174 1/20 0.49
LTA4H P09960 1/20 0.47
MMP2 P08253 2/20 0.47
MMP3 P08254 2/20 0.47
MMP9 P14780 2/20 0.47
MMP13 P45452 2/20 0.47
MGLL Q99685 1/20 0.46
NTRK1 P04629 1/20 0.45
IGF1R P08069 1/20 0.45
FGFR1 P11362 1/20 0.45
NTRK3 Q16288 1/20 0.45
NTRK2 Q16620 1/20 0.45
CTSG P08311 1/20 0.42
CMA1 P23946 1/20 0.42
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24155915 0.86 CRBN (0.59) CRBNDDB1MMP2MMP9MMP13
SCHEMBL31674504 0.85 MMP13 (0.54) CRBNDDB1MMP13NTRK1IGF1R
SCHEMBL31674502 0.85 SCN9A (0.54) CRBNDDB1MMP2MMP3MMP9
SCHEMBL21995539 0.85 CRBN (0.52) CRBNDDB1PLCG1MMP13MGLL
SCHEMBL24155471 0.85 SCN9A (0.54) CRBNDDB1MMP2MMP3MMP9
SCHEMBL31674505 0.85 CRBN (0.52) CRBNDDB1PLCG1MMP13MGLL
SCHEMBL24156356 0.85 CRBN (0.52) CRBNDDB1LTA4HTDP1
SCHEMBL24156369 0.85 MMP13 (0.54) CRBNDDB1MMP13NTRK1IGF1R
SCHEMBL5376083 0.85 CRBN (1.00) CRBNDDB1ALDH1A1MAPTALOX15
Hydrochloric Acid SCHEMBL30874155 0.83 CRBN (0.96) CRBNDDB1ALDH1A1MAPTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY SLC6A11, SCN1A, SCN1B CRBN 3575/4885DDB1 4483/4885PLCG1 3628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.